258 related articles for article (PubMed ID: 28579282)
21. Increased PD-L1 expression in breast and colon cancer stem cells.
Wu Y; Chen M; Wu P; Chen C; Xu ZP; Gu W
Clin Exp Pharmacol Physiol; 2017 May; 44(5):602-604. PubMed ID: 28107571
[TBL] [Abstract][Full Text] [Related]
22. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Wang L
J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
[TBL] [Abstract][Full Text] [Related]
23. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas.
Yan D; Zhao Q; Du Z; Li H; Geng R; Yang W; Zhang X; Cao J; Yi N; Zhou J; Tang Z
Sci Rep; 2022 Apr; 12(1):6698. PubMed ID: 35461367
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
27. A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway.
Meng J; Li P; Zhang Q; Yang Z; Fu S
Oncotarget; 2014 Jul; 5(13):4683-93. PubMed ID: 24970813
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
29. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
30. Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer.
Speers C; Zhao S; Liu M; Bartelink H; Pierce LJ; Feng FY
Clin Cancer Res; 2015 Aug; 21(16):3667-77. PubMed ID: 25904749
[TBL] [Abstract][Full Text] [Related]
31. Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Schulz D; Streller M; Piendl G; Brockhoff G; Reichert TE; Menevse AN; Beckhove P; Hautmann MG; Bauer RJ; Ettl T
Carcinogenesis; 2020 Jul; 41(7):984-992. PubMed ID: 31637423
[TBL] [Abstract][Full Text] [Related]
32. Uncovering a novel DNA repair-related radiosensitivity model for evaluation of radiotherapy susceptibility in uterine corpus endometrial cancer.
Yang H; Qiu Y; Chen J; Lai J
Heliyon; 2024 Apr; 10(8):e29401. PubMed ID: 38628740
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501
[TBL] [Abstract][Full Text] [Related]
34. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
36. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
[TBL] [Abstract][Full Text] [Related]
37. A Radiosensitivity Gene Signature and XPO1 Predict Clinical Outcomes for Glioma Patients.
Wu S; Qiao Q; Li G
Front Oncol; 2020; 10():871. PubMed ID: 32612949
[No Abstract] [Full Text] [Related]
38. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
39. Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
Cui Y; Li B; Pollom EL; Horst KC; Li R
Clin Cancer Res; 2018 Oct; 24(19):4754-4762. PubMed ID: 29921729
[No Abstract] [Full Text] [Related]
40. An Integrative Model of miRNA and mRNA Expression Signature for Patients of Breast Invasive Carcinoma with Radiotherapy Prognosis.
Bing Z; Tian J; Zhang J; Li X; Wang X; Yang K
Cancer Biother Radiopharm; 2016 Sep; 31(7):253-60. PubMed ID: 27610468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
